

FORMATO EUROPEO PER IL CURRICULUM VITAE



INFORMAZIONI PERSONALI

Nome **SIMONI NICOLA**

Indirizzo Azienda Ospedaliero Universitaria Parma
UOC di Radioterapia
Via Gramsci 14, 43126 Parma, Italia

Telefono 0521-702507

E-mail nicolasimoni81@gmail.com
nsimoni@ao.pr.it

Nazionalità Italiana

Data di nascita 30 gennaio 1981

POSIZIONE ATTUALE RICOPERTA ED ESPERIENZA LAVORATIVA

16 agosto 2023 - oggi
Azienda Ospedaliero Universitaria Parma
UOC di Radioterapia
DIRIGENTE MEDICO – DIREZIONE STRUTTURA SEMPLICE
IN RADIOTERAPIA AVANZATA

31 dicembre 2020 – 15 agosto 2023
Azienda Ospedaliero Universitaria Parma
UOC di Radioterapia
DIRIGENTE MEDICO
(con “delega per la gestione clinica e organizzativa” dell'UOC di Radioterapia da luglio 2022 a giugno 2023)

04 gennaio 2016 – 30 dicembre 2020
Azienda Ospedaliero Universitaria Integrata Verona
UOC di Radioterapia
DIRIGENTE MEDICO

13 luglio 2015 – 03 gennaio 2016
Arcispedale Santa Maria Nuova IRCCS Reggio Emilia,
UOC di Radioterapia
MEDICO A CONTRATTO LIBERO PROFESSIONALE

ISTRUZIONE E FORMAZIONE

2021
Master in Biostatistica per la Ricerca Clinica e la Pubblicazione Scientifica, Università degli Studi di Padova

2015
Specializzazione in Radioterapia, Università degli Studi di Parma
Tesi di ricerca sull'argomento: “Radioterapia ad intensita' modulata (IMRT) nel trattamento integrato dei carcinomi del rinofaringe” - Voto di Specializzazione 50/50 con lode

2009
Corso di laurea specialistica in Medicina e Chirurgia, Università degli Studi di Parma
Tesi sperimentale sull'argomento: “Radioterapia conformazionale nel trattamento integrato degli astrocitomi ad alto grado”- Voto di laurea 110/110

**PUBBLICAZIONI
(FULL PAPERS)**

Alterio D, Ciardo D, Preda L, Argenone A, Caspiani O, Micera R, Ruvo Redda MG, Russi EG, Bianchi E, Orlandi E, Bacigalupo A, Busetto M, Cante D, Deantonio L, De Sanctis V, Franco P, Lastrucci L, Marucci L, Merlotti A, Molteni M, Pajar F, Rampino M, Santoro L, Ferrari A, Bazzani F, Caputo M, Laudati A, Borzillo V, Falivene S, **Simoni N**, Vigo F, Iannacone E, Reali A, Bonanni A, Leone M, Giannello L, Taglianti RV, Orecchia R. Contouring of the Pharyngeal Superior Constrictor Muscle (PSCM). A cooperative study of the Italian Association of Radiation Oncology (AIRO) Head and Neck Group. *Radiother Oncol*. 2014 Sep;112(3):337-42.

Micera R, **Simoni N**, Liguoro M, Vigo F, Grondelli C, Galaverni M, Roncali M, Pagano M, Iotti C. The key role of ¹⁸F-FDG PET/CT for correct diagnosis, staging, and treatment in a patient with simultaneous NPC and TB lymphadenitis: case report. *Tumori*. 2016 Nov 11;102 (Suppl. 2).

Caravatta L, Cellini F, **Simoni N**, Rosa C, Niespolo RM, Lupattelli M, Picardi V, Macchia G, Sainato A, Mantello G, Dionisi F, Rosetto ME, Fusco V, Navarra F, De Paoli A, Guido A, Vecchi C, Basilico R, Cianci R, Delli Pizzi A, Di Nicola M, Mattiucci GC, Valentini V, Morganti AG, Genovesi D. Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a multi-institutional contouring study on behalf of the AIRO group for gastrointestinal cancers. *Acta Oncol*. 2019 Jan 11:1-9.

Arcelli A, Guido A, Buwenge M, **Simoni N**, Mazzarotto R, Macchia G, Deodato F, Cilla S, Bonomo P, Scotti V, Belgioia L, Tolento G, Cellini F, Grassi E, Di Marco M, Casadei R, Morganti AG, Cammelli S. Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). *Anticancer Res*. 2020 Jan;40(1):465-472.

Cellini F, Arcelli A, **Simoni N**, Caravatta L, Buwenge M, Calabrese A, Brunetti O, Genovesi D, Mazzarotto R, Deodato F, Mattiucci GC, Silvestris N, Valentini V, Morganti AG. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. *Cancers (Basel)*. 2020 Jun 29;12(7):1729.

Simoni N, Micera R, Paiella S, Guariglia S, Zivelonghi E, Malleo G, Rossi G, Addari L, Giuliani T, Pollini T, Cavedon C, Salvia R, Milella M, Bassi C, Mazzarotto R. Hypofractionated Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. *Clin Oncol (R Coll Radiol)*. 2020 Jul 15: S0936-6555(20)30275-2.

Arcelli A, Buwenge M, Macchia G, Bertini F, Guido A, Deodato F, Cilla S, Scotti V, Rosetto ME, Djan I, Parisi S, Mattiucci GC, Cellini F, Fiore M, Bonomo P, Belgioia L, Niespolo RM, Gabriele P, Di Marco M, **Simoni N**, Mazzarotto R, Morganti AG; AIRO (Italian Association of Radiation Oncology and Clinical Oncology) Gastrointestinal Study Group. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1). *Cancer Med*. 2020 Sep 10.

Simoni N, Micera R, Rossi G, Giri MG, Pavarana M, Muraglia A, Cernusco NLV, DE Liguoro M, Guariglia S, Cavedon C, Milella M, Mazzarotto R. Predictors of Local Control for Stereotactic Ablative Radiotherapy (SABR) in Pulmonary Oligometastases from Gastrointestinal Malignancies. *Anticancer Res*. 2020 Oct;40(10):5901-5907

La Mendola R, Bencivenga M, Torroni L, Alberti L, Sacco M, Casella F, Ridolfi C, **Simoni N**, Micera R, Pavarana M, Verlato G, Giacomuzzi S. Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy. *Ann Surg Oncol*. 2021 Jun;28(6):3034-3043.

Simoni N, Pavarana M, Micera R, Weindelmayer J, Mengardo V, Rossi G, Cenzi D, Tomezzoli A, Del Bianco P, Giacomuzzi S, De Manzoni G, Mazzarotto R. Long-Term Outcomes of Induction Chemotherapy Followed by Chemo-Radiotherapy as Intensive Neoadjuvant Protocol in Patients with Esophageal Cancer. *Cancers (Basel)*. 2020 Dec 3;12(12):3614.

Simoni N, Rossi G, Benetti G, Zuffante M, Micera R, Pavarana M, Guariglia S, Zivelonghi E, Mengardo V, Weindelmayer J, Giacomuzzi S, de Manzoni G, Cavedon C, Mazzarotto R. ¹⁸F-FDG PET/CT Metrics Are Correlated to the Pathological Response in Esophageal Cancer Patients Treated with Induction Chemotherapy Followed by Neoadjuvant Chemo-Radiotherapy. *Front Oncol*. 2020 Nov 27; 10:599907.

Mazzarotto R, **Simoni N**, Guariglia S, Rossi G, Micera R, De Robertis R, Pierelli A, Zivelonghi E, Malleo G, Paiella S, Salvia R, Cavedon C, Milella M, Bassi C. Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar. *Front Oncol*. 2020 Dec 17; 10:600940.

Paiella S, Malleo G, **Simoni N**, Micera R, Guariglia S, Cavedon C, Marchegiani G, Esposito A, Landoni L, Casetti L, Tuveri M, Milella M, Secchettin E, Manzini G, Bovo C, De Pastena M, Fontana M, Salvia R, Mazzarotto R, Bassi C. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma. *BMC Cancer*. 2021 Feb 16;21(1):165.

Caravatta L, Lupattelli M, Mantello G, Gambacorta MA, Chiloio G, Di Tommaso M, Rosa C, Gasparini L, Morganti AG, Picardi V, Niespolo RM, Osti MF, Montrone S, **Simoni N**, Boso C, Facchin F, Deidda MA, Piva C, Guida C, Ziccarelli L, Munoz F, Ivaldi GB, Marchetti V, Franzoni P, Spatola C, Franco P, Donato V, Genovesi D; Gastrointestinal Study Group of AIRO (Italian Association of Radiation Oncology and Clinical Oncology). Treatment Volume, Dose Prescription and Delivery Techniques for Dose-intensification in Rectal Cancer: A National Survey. *Anticancer Res*. 2021 Apr;41(4):1985-1995.

Rossi G, **Simoni N**, Paiella S, Rossi R, Venezia M, Micera R, Malleo G, Salvia R, Giuliani T, Di Gioia A, Auriemma A, Milella M, Guariglia S, Cavedon C, Bassi C, Mazzarotto R. Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. *Front Oncol*. 2021 Apr 20; 11:662205.

Rossi G, Altabella L, **Simoni N**, Benetti G, Rossi R, Venezia M, Paiella S, Malleo G, Salvia R, Guariglia S, Bassi C, Cavedon C, Mazzarotto R. Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy. *World J Gastrointest Oncol* 2022; 14(3): 703-715.

Simoni N, Rossi G, Cellini F, Vitolo V, Orlandi E, Valentini V, Mazzarotto R, Sverzellati N, D'Abbiere N. Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm? *Life (Basel)*. 2022 Mar 22;12(4):465.

Arcelli A, Tarantino G, Cellini F, Buwenge M, Macchia G, Bertini F, Guido A, Deodato F, Cilla S, Scotti V, Rosetto ME, Djan I, Parisi S, Mattiucci GC, Fiore M, Bonomo P, Belgioia L, Niespolo RM, Gabriele P, Di Marco M, **Simoni N**, Ma J, Strigari L, Mazzarotto R, Morganti AG. Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1). *Curr Oncol*. 2023 Jun 10;30(6):5690-5703.

Francolini G, Garlatti P, Di Cataldo V, Triggiani L, **Simoni N**, Detti B, Lorenzetti V, Colombo F, Morelli V, Ganovelli M, Caprara L, Orsatti C, Burchini L, Frosini G, Bertini N, Loi M, Simontacchi G, Greto D, Desideri I, Meattini I, Livi L. Pattern of recurrence after stereotactic body radiotherapy for para-aortic oligo-recurrent prostate cancer, a multicentric analysis. *Radiol Med*. 2023 Aug 19.

Borghetti P, Facheris G, Ciammella P, Galaverni M, Granello L, Scotti V, Franceschini D, Romei A, Giaj Levra N, Federico M, La Vecchia M, Merlotti A, Sepulcri M, Piperno G, Marvaso G, **Simoni N**, Ali E, Pontoriero A, Cappelli A, Dionisi V, Menis J, Martino A, Vagge S, Canova S, Montesi G, Cuccia F, Boldrini L, Franzese C, Grisanti S, Bruni A, Scorsetti M. Stereotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort. *Clin Lung Cancer*. 2023 Nov 17:S1525-7304(23)00240-1.

Francolini G, Porreca A, Facchini G, Santini D, Bruni A, **Simoni N**, Trovò M, Osti MF, Fornarini G, Sisani M, Di Cataldo V, Detti B, Garlatti P, Bertini N, Serni S, Minervini A, Livi L. PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients. *Med Oncol*. 2023 Dec 29;41(1):39.

Giudice GC, Maruzzo M, Verzoni E, Procopio G, Bimbatti D, Sepe P, Maines F, Grillone F, Cavo A, Santoni M, Cordua N, Pecoraro G, Prati V, Napoli MD, Ollari E, Caruso G, **Simoni N**, Campobasso D, Buti S. Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney. *Clin Genitourin Cancer*. 2024 Oct;22(5):102186.

Corianò M, Lazzarin A, Maffezzoli M, Santoni M, Mazzaschi G, Rodella S, **Simoni N**, Lai E, Maruzzo M, Basso U, Bimbatti D, Iacovelli R, Anghelone A, Fiala O, Rebuzzi SE, Fornarini G, Lolli C, Massari F, Rosellini M, Mollica V, Nasso C, Acunzo A, Silini EM, Quaini F, De Filippo M, Brunelli M, Banna GL, Rescigno P, Signori A, Buti S. Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations. *Immunotherapy*. 2025 Jan;17(1):25-35.

Maffezzoli M, Signori A, Campobasso D, Giudice GC, **Simoni N**, Filippo M, Silini EM, Buti S. External Validation of the GGrade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma. *Technol Cancer Res Treat*. 2025 Jan-Dec;24:15330338251329848.

Maffezzoli M, Giudice GC, Iovane G, Manini M, Rapacchi E, Caruso G, **Simoni N**, Ferretti S, Puliatti S, Campobasso D, Buti S. The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review. *Oncol Res*. 2025 Mar 19;33(4):741-757.

Peroni M, Leonetti A, Minari R, Verzè M, Gnetti L, Bottarelli L, Azzoni C, Galaverni M, **Simoni N**, Missale G, Biasini E, Tiseo M. BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature. *JTO Clin Res Rep*. 2025 Jun 19;6(8):100867.

F. Mastroleo, R. Villa, M. Zaffaroni, M.G. Vincini, C. Franzese, L. Nicosia, F. Matrone, A. Donofrio, A. Magli, L. Triggiani, S. Barra, G. Timon, M. Augugliaro, V. Burgio, G. Francolini, M. Hasterok, M. Miszczyk, **N. Simoni**, C. Spatola, F. Alongi, S. Arcangeli, M. Scorsetti, G. Marvaso, B.A. Jereczek-Fossa. Penalized-Survival Nomogram Predicts 5-Year Metastasis-Free Survival After Salvage Radiotherapy for Post-Prostatectomy patients: a Multicenter Study. *Clin Genitourin Cancer*. 2025 Aug (Article in Press).

ABSTRACT E POSTER CONGRESSUALI

Esperienza clinica di Parma nella tossicità acuta dei pazienti affetti da neoplasia del testa-collo trattati con VMAT (RapidArc) e tecnica SIB (Simultaneous Integrated Boost). XXII Congresso Nazionale AIRO 2012

La tecnica VMAT nel trattamento dei pazienti affetti da carcinoma polmonare non a piccole cellule: valutazione della tossicità acuta in associazione o meno con la chemioterapia. XXII Congresso Nazionale AIRO 2012

Tossicità acuta in pazienti affetti da neoplasia prostatica trattati con VMAT (RapidArc): la nostra esperienza. XXII Congresso Nazionale AIRO 2012

Le reirradiazioni delle recidive e dei tumori secondari nel distretto testa collo: esperienza monoistituzionale. XXIII Congresso Nazionale AIRO 2013

Re-irradiation for recurrence and second primary head and neck cancer: A single center experience. 2014 Supplement, *Radiotherapy and Oncology*, Vol. 111, S33

Radioterapia stereotassica esclusiva versus irradiazione panencefalica più boost simultaneo nelle metastasi cerebrali: valutazione degli outcomes clinici. XXIV Congresso Nazionale AIRO 2014

Esperienza mono-istituzionale nel trattamento radiante del carcinoma rinofaringeo mediante tecnica ad intensità modulata. XXIV Congresso Nazionale AIRO 2014

Multi-variable models of acute urinary toxicity: final results of a large prospective study. April 2015, *Radiotherapy and Oncology*, Vol. 115, S129–S130

Neoadjuvant chemoradiotherapy followed by esophagectomy in patients with locally advanced esophageal cancer: the experience of Department of Radiation Oncology IRCCS–ASMN Reggio Emilia. VIII Congresso AIRO Giovani 2015

RE-irradiation (RE-RT) of head and neck cancer (HNC): Dose accumulation using deformable image registration (DIR) and comparison with rigid registration (RIR). February 2016, *Physica Medica: European Journal of Medical Physics*, Vol. 32, p7–8

RapidPlan models based on helical tomotherapy (HT) prostate plans for VMAT optimization February 2016, *Physica Medica: European Journal of Medical Physics*, Vol. 32, p8

Clinical and dose predictors for the incidence of late urinary symptoms after radical radiotherapy for prostate cancer. February 2016, *Physica Medica: European Journal of Medical Physics*, Vol. 32, p49

Multivariable models for urinary symptoms at 6-24 months after radical RT of prostate cancer. April 2016, Radiotherapy and Oncology, Vol. 115, S129–S130

Stereotactic body radiation therapy (SBRT) in pancreatic cancer: a single institutional experience. April 2018, Radiotherapy and Oncology, Vol. 127, S788–S789

MRI for GTV delineation in pancreatic cancer: preliminary results of a multi-institutional study. April 2018, Radiotherapy and Oncology, Vol. 127, S400–S401

Neoadjuvant Chemoradiotherapy In Esophageal Tumors: Real Life Beyond Study Protocols. Diseases of the Esophagus, Volume 31, Issue 13, 1 September 2018

SBRT with Simultaneous Integrated Protection (SIP) in Unresectable Pancreatic Cancer: A Mono-Institutional Experience. November 01, 2018, International Journal of Radiation Oncology Biology Physics, Vol. 102, Issue 3, e77

Radioterapia stereotassica nelle neoplasie pancreatiche: l'esperienza dell'AOUI Verona. XXVIII Congresso Nazionale AIRO. Sessione Poster. Rimini 02-04 novembre 2018

Gross Tumor Volume delineation in pancreatic cancer using MRI: final results of a multicenter study. Radiotherapy and Oncology, April 2019 Volume 133, Supplement 1, Pages S421–S422

SBRT in locally advanced pancreatic cancer: a real-life study (PAULA-1). Radiotherapy and Oncology, April 2019, Volume 133, Supplement 1, Pages S772–S773

SBRT vs chemoradiation: a case-control study (PAULA-2). Radiotherapy and Oncology, April 2019, Volume 133, Supplement 1, Pages S773–S774

Long-Term Outcomes Using Electron IORT APBI for Early-Stage Breast Cancer: The Verona University Hospital Experience. International Journal of Radiation Oncology Biology Physics September 1, 2019 Volume 105, Issue 1, Supplement, Pages E17–E18

SBRT with Simultaneous Integrated Protection: Incidence and Pattern of Recurrence in Borderline Resectable and Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics September 1, 2019 Volume 105, Issue 1, Supplement, Page E 246

Surgical Margins Status and Postoperative Complications after SBRT as Neoadjuvant Approach for Pancreatic Cancer. Abstract Book AIRO 2019

Long-Term Outcomes Using Electron IORT APBI for Early-Stage Breast Cancer: The Verona University Hospital Experience. Abstract Book AIRO 2019

A Dosimetric Comparison of Left-Sided Breast Radiotherapy Techniques to Treat Chest Wall and Regional Nodes and Heart Sparing. Abstract Book AIRO 2019

Stereotactic Body Radiotherapy +/- Chemotherapy Vs External Beam Radiotherapy +/- Chemotherapy: An Italian Multicentric Case-Control Study About Locally Advanced Pancreatic Cancer (PAULA-2). Abstract Book AIRO 2019

Evaluation of Setup Uncertainties and Interfraction Organ Motion in SBRT for Pancreatic Cancer using Intratumoral Fiducial Markers. Abstract Book AIRO 2019

SBRT With Simultaneous Integrated Boost and Protection: Incidence and Pattern of Recurrence in Borderline Resectable and Locally Advanced Pancreatic Cancer. Abstract Book AIRO 2019

SBRT vs conventionally fractionated radio- chemotherapy for pancreatic cancer: a case-control study. ESTRO 2020

Postoperative complications and margins status after neoadjuvant SBRT for pancreatic cancer. ESTRO 2020

Intensive Neoadjuvant Chemoradiation Protocol for Locally Advanced Esophageal Cancer: Results in Real Life Population. International Journal of Radiation Oncology, Biology, Physics, Volume 108, Issue 3, e626 - e627

CT Texture Analysis Effect of Neoadjuvant Stereotactic Body Radiation Therapy (SBRT) in Borderline Resectable and Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology, Biology, Physics, Volume 108, Issue 3, e782

Value Of 18F-FDG/PET For Predicting Response to Intensive Neoadjuvant Chemoradiation Protocol in Esophageal Cancer. Abstract Book AIRO 2020

SBRT For Locally Advanced Pancreatic Cancer: We Are Raising the Bar. Abstract Book AIRO 2020

Stereotactic Body Radiotherapy (SBRT) Vs. Conventional Fractionated Radiotherapy for Unresectable Pancreatic Cancer in Elderly Patients. Abstract Book AIRO 2020

Intensive Neoadjuvant Chemoradiation Protocol for Locally Advanced Esophageal Cancer: A Mono-Institutional Experience. Abstract Book AIRO 2020

Pre-Treatment Primary Tumor Stage Is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma and Adenocarcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy. Abstract Book AIRO 2020

Hypofractionated Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. Abstract Book AIRO 2020

Prediction Of Resection Margin Status After Induction Chemotherapy and SBRT in Patients with Unresectable Pancreatic Cancer Using Ct Texture Analysis. Abstract Book AIRO 2020

Management Of Lung Cancer During the Covid-19 Pandemic: The Experience of Italian Center. Abstract Book AIRO 2020

Stereotactic Body Radiotherapy (SBRT) For Patients with Pulmonary Oligometastases from Gastrointestinal Primary Tumors. Abstract Book AIRO 2020

Incidence and pattern of LRR in esophageal cancer patients treated with iCT followed by neoadj CTRT. ESTRO 2021

Outcome analysis in locally advanced pancreatic cancer: a predictive model (PAULA-1). ESTRO 2021

Stereobody radiotherapy vs chemoradiation in elderly with locally advanced pancreatic cancer. ESTRO 2021

Locally Advanced Pancreatic Cancer Treated with Risk Adapted Ablative Radiation Therapy: May Computed Tomography Radiomic Parameters Predict Resectability? Abstract Book AIRO 2021

Outcome Analysis of Different Therapeutic Options in Locally Advanced Pancreatic Cancer: A Predictive Model from A Multicenter Study (PAULA-1). Abstract Book AIRO 2021

Esophageal Cancer Treated with Induction Chemotherapy Followed by Neoadjuvant Chemo-Radiotherapy: Incidence and Pattern of Loco-Regional Recurrence. Abstract Book AIRO 2021

Risk Adapted Ablative Radiotherapy (RADAR) Approach for Locally Advanced Pancreatic Cancer (LAPC), After Intensive Chemotherapy. Abstract Book AIRO 2021

Radiotherapy In Non-Vestibular Neuroma: A Case Report. Abstract Book AIRO 2021

Planning Strategies, Motion Management, Accuracy and Delivery for Stereotactic Body Radiotherapy in Pancreatic Cancer. An Update of a National Survey By The AIRO Gastrointestinal Study Group. Abstract Book AIRO 2022

Stereotactic Ventricular Arrhythmia Radioablation for Ventricular Tachycardia: Single Center First Experience. Abstract Book AIRO 2022

Radiomic-Based Stratification of High-Risk Prostate Cancer Patient for The Prediction of Biochemical Free Survival. M. Maddalo. Abstract Book AIRO 2022

Stereotactic Body Radiotherapy in Pancreatic Cancer: An Update of a National Survey by the AIRO Gastrointestinal Study Group. Abstract Book AIRO 2022

Predictors Of Local Control and Survival for Stereotactic Fractionated Radiotherapy (SFRT) In Patients with Breast Cancer Brain Metastases. Abstract Book AIRO 2022

A Pattern of Care Report on The Management of Patients with Esophageal Cancer - A Survey by The Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Tumors Study Group. Abstract Book AIRO 2022

A Snapshot on The Management of Gastroesophageal Junction Cancer Patients – A Survey by The Italian Association of Radiotherapy and Clinical Oncology (Airo) Gastrointestinal Tumors Study Group. Abstract Book AIRO 2022.

Stereotactic Radiotherapy for Pancreatic Cancer: An Update of A National Survey. ESTRO 2023.

Management of esophageal cancers. Survey by the AIRO Gastrointestinal Tumors Study Group. ESTRO 2023.

Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia: Single Center Experience. ESTRO 2023.

Effectiveness of Non-coplanar Monoisocenter Multifraction Radiosurgery for Multiple Brain Metastases. ESTRO 2023.

Stereotactic Body Radiation Therapy with MRI-Defined Focal Simultaneous Integrated Boost for Patients with Localized Prostate Cancer: Acute Toxicity and Dosimetry Results from a Prospective Study. XXXIII Congresso Nazionale SIUrO 2023.

Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer: A Retrospective Multi-Center Analysis On 125 Patients. Abstract Book AIRO 2023.

Management and Oncological Outcomes of Local Persistence and Recurrence of Anal Squamocell Carcinoma after Radio-chemotherapy: a Subgroup Analysis of a Multi-Center Study of The AIRO Gastrointestinal Study Group. Abstract Book AIRO 2023.

Ventricular Tachycardia Ablation by Stereotactic Radiotherapy: A Large Multi-Center Cohort Analysis on Efficacy and Homogeneity of the Approach. Abstract Book AIRO 2023.

Is Surgery the Only Chance to Obtain a Long-Term Prognosis in Patients with Pancreatic Cancer? A Secondary Analysis of a Multi-Center Observational Study (Paula-1). Abstract Book AIRO 2023.

Clinical Efficacy of Stereotactic Body Radiotherapy as Adrenal Gland Metastasis-Directed Therapy in Oligometastatic Patients. Abstract Book AIRO 2023.

Stereotactic Body Radiation Therapy with MRI-Defined Focal Simultaneous Integrated Boost for Patients with Localized Prostate Cancer: Acute Toxicity and Dosimetry Results from a Prospective Study. Abstract Book AIRO 2023.

Effectiveness and Safety of Non-Coplanar Monoisocenter Multifraction Radiosurgery for Multiple Brain Metastases. Abstract Book AIRO 2023.

Apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer: A randomized trial (PERSIAN). ASCO Genitourinary Cancers Symposium 2024.

PSICHE trial (NCT05022914): PSMA guided approach for biochemical relapse after prostatectomy- a prospective trial. EAU 2024.

Safety of judicious stereotactic ablative radiotherapy for central and ultra-central lung tumors. ESTRO 2024.

Clinical efficacy of SBRT as adrenal gland metastasis-directed therapy in oligometastatic patients. ESTRO 2024.

Radioablation for ventricular tachycardia: a cohort multicenter analysis of efficacy and homogeneity. ESTRO 2024.

SBRT in locally advanced pancreatic cancer: a multicenter analysis on 125 patients. ESTRO 2024.

Secondary analysis of a multicenter observational study in pancreatic cancer. ESTRO 2024.

PSICHE trial (NCT05022914), a trial testing a PSMA guided approach for relapse after prostatectomy. ESTRO 2024.

SBRT with MRI-defined boost for prostate cancer: results from a prospective observational study. ESTRO 2024.

PSMA guided approach for biochemical relapse after prostatectomy - PSICHE trial (NCT05022914). AIRO 2024.

Stereotactic body radiotherapy (SBRT) for localized prostate cancer: 1- year toxicity and quality of life results from an observational prospective study. AIRO 2024.

Ventricular tachycardia ablation through radiation therapy (VT-ART): a wide cohort multicenter analysis of efficacy and homogeneity of approach. AIRO 2024.

Local control and bronchial toxicity of stereotactic ablative radiotherapy (SABR) for central and ultra-central lung tumors. AIRO 2024.

KV-triggered fiducials tracking and magnitude of intra-fraction prostate motion during prostate stereotactic body radiation therapy (SBRT). AIRO 2024.

PERSIAN trial: Early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer. Francolini, Di Cataldo, Garlatti, Caini, Bruni, **Simoni**, Augugliaro, et al. ASCO Genitourinary Cancers Symposium 2025.

Stereotactic Radiosurgery for Extracranial Oligometastatic Patients: Preliminary Results from a Prospective Observational Study. ESTRO 2025.

Stereotactic Body Radiotherapy as Adrenal Gland Metastasis-Directed Therapy in Oligometastatic Patients. ESTRO 2025.

Early Complications, Quality Distribution and Dosimetric Impact of Hyaluronic Rectal Spacer for Prostate Cancer Stereotactic Body Radiation Therapy. ESTRO 2025.

Dosimetric and Clinical Predictors of Acute Radiation Pneumonitis in Patients Pre-Treated with Immune Checkpoint Inhibitors. ESTRO 2025.

PERSIAN TRIAL (NCT03449719): Apalutamide and stereotactic body radiation therapy in patients affected by hormone-sensitive prostate cancer. ESTRO 2025.

LINGUA MADRE ITALIANA

ALTRE LINGUE INGLESE

**ULTERIORI CAPACITÀ E
COMPETENZE TECNICO-
PROFESSIONALI**

Stesura di progetti di ricerca e partecipazione/conduzione di studi clinici (fase II e III, osservazionali prospettici), tra cui per la patologia uro-oncologica:

- Principal Investigator locale dello studio Effectiveness of the SpaceOAR Vue System in Subjects with Prostate Cancer being Treated with Stereotactic Body Radiotherapy - SABRE U0702 (NCT04905069) studio randomizzato di fase III, internazionale
- Principal Investigator locale dello studio PSMA Guided Approach for biochemical Relapse After Prostatectomy - PSICHE (NCT05022914)
- Principal Investigator locale dello studio APalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer PERSIAN (NCT05717660) studio randomizzato di fase II, multicentrico
- Co-investigatore dello studio Real-life Stereotactic Body Radiotherapy for Localized Prostate Cancer - Stereo-PCa Study
- Co-investigatore dello studio Efficacy of PERioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer - The PE-PE study (EudraCT Number 2022-001077-30) studio randomizzato di fase II, multicentrico
- Principal Investigator locale dello studio Ultra-hypofractionated radiotherapy and concomitant oral Relugolix for treatment of intermediate risk prostate cancer - Ultra- HERO trial (EU CT Number: 2024-518388-37-00) studio di fase II, multicentrico
- Principal Investigator locale dello studio Early Salvage Stereotactic Radiotherapy (esSBRT) for Biochemical Failure after RP: A Phase II Study (NCT05667636) studio di fase II, multicentrico.

Impegnato inoltre in diversi altri studi prospettici e retrospettivi, sia multicentrici che monocentrici, che coinvolgono la UOC Radioterapia di Parma

Stesura grant per progetti di ricerca
- vincitore grant 2023 per progetto "Acquisizione di un innovativo sistema di Surface Guided Radiation Therapy (SGRT)", Fondazione Cariparma, valore 373.320 euro

Utilizzo software statistici (R Project for Statistical Computing, SPSS)

**PARTECIPAZIONE GRUPPI
LAVORO**

Estensore documento PDTA Uro-Oncologico e Referente di Patologia del PDTA Uro-Oncologico per la UOC di Radioterapia dell'Azienda Ospedaliero Universitaria Parma

Estensore documento PDTA Pancreas e Vie Biliari e Referente di Patologia del PDTA Pancreas e Vie Biliari per la UOC di Radioterapia dell'Azienda Ospedaliero Universitaria Parma

Estensore documento PDTA Colon-Retto e Referente di Patologia del PDTA Colon-Retto per la UOC di Radioterapia dell'Azienda Ospedaliero Universitaria Parma

Estensore documento PDTA Neoplasie Toraciche Azienda Ospedaliero Universitaria Parma

SOCIETA' SCIENTIFICHE

Membro AIRO (Associazione Italiana Radioterapia Oncologica)
2022-2023: coordinamento Gruppo di Studio AIRO Gastrointestinale – Consigliere
2022-2025: coordinamento Gruppo di Studio AIRO Trattamenti Ablativi Non Oncologici – Consigliere

Membro ESTRO (European Society for Radiotherapy and Oncology)

Membro SIURo (Società Italiana di Urologia Oncologica)

ATTIVITA' DIDATTICA

Anno accademico 2021-2022, 2022-2023, 2023-2024: Professore a Contratto per il Corso di Laurea in Tecniche di Radiologia Medica, per Immagini e Radioterapia (Scienze tecniche mediche applicate in radioterapia) del Dipartimento di Medicina e Chirurgia, Università degli Studi di Parma

Anno accademico 2024-2025: Professore a Contratto Titolare di Insegnamento per il Corso di Laurea in Tecniche di Radiologia Medica, per Immagini e Radioterapia (Scienze tecniche mediche applicate in radioterapia) del Dipartimento di Medicina e Chirurgia, Università degli Studi di Parma

Dichiaro che il presente Curriculum Vitae è redatto sotto propria responsabilità e consapevole delle sanzioni penali, nel caso di dichiarazioni non veritiere, di formazione o uso di atti falsi, richiamate dall'art. 76 D.P.R. 445 del 28/12/2000, e della decadenza dai benefici conseguiti al provvedimento eventualmente emanato sulla base di dichiarazione non veritiera ai sensi dell'art. 75 dello stesso D.P.R.

Autorizzo il trattamento dei dati personali, ivi compresi quelli sensibili, ai sensi e per gli effetti del Decreto Legge 196/2003.

Data 11/08/2025
Firma Nicola Simoni

Parma, 11 agosto 2025

Oggetto: “Candidatura Coordinamento Gruppo di Studio Uro-oncologico”

Documento di candidatura come Consigliere del Gruppo di Studio AIRO Uro-oncologico per il biennio 2026-2027

Care Colleghe e Cari Colleghi

Mi rivolgo a voi per sottoporvi la mia candidatura come Consigliere del Gruppo di Studio AIRO Uro-oncologico per il biennio 2026-2027. Sono Nicola Simoni, Radio-Oncologo attualmente Responsabile della Struttura Semplice di Radioterapia Avanzata presso l'Unità Operativa Complessa di Radioterapia dell'Azienda Ospedaliero Universitaria di Parma.

Nel corso della mia esperienza professionale, svoltasi presso le UO di Radioterapia di Reggio Emilia, Verona e infine Parma, mi sono da sempre occupato delle neoplasie urologiche. Nella mia esperienza a Parma, mi sono in particolare dedicato all'implementazione in pratica clinica della SBRT per le neoplasie primitive di prostata e rene, nonché per il trattamento della malattia oligometastatica, con protocolli di radiochirurgia body e con particolare interesse all'integrazione con nuovi farmaci. Attualmente, come Referente di Patologia, partecipo attivamente al Gruppo Multidisciplinare (PDTA) Uro-Oncologico e sono referente di diversi studi clinici indirizzati alla patologia GU attivi presso la mia Unità Operativa.

Sarei onorato e felice di poter mettere a disposizione le mie competenze, il mio entusiasmo e il mio impegno per contribuire all'attività di un Gruppo con una storia così importante, per promuovere e rafforzare il ruolo centrale e imprescindibile del Radio-Oncologo nella gestione multidisciplinare di queste patologie, in un dialogo costante e proficuo con altri specialisti e società scientifiche, per accelerare l'adozione e implementazione sul territorio nazionale delle tecniche più innovative, migliorando così l'accesso dei pazienti alle cure, e ancora, per stimolare una ricerca clinica di qualità e per supportare la formazione di giovani specialisti, garantendo un futuro di eccellenza per la nostra disciplina. Tutto questo in continuità con l'eccellente lavoro svolto dal precedente Direttivo, con l'obiettivo di proseguire il percorso di crescita e innovazione del Gruppo. Vi ringrazio anticipatamente per l'attenzione e rimango a disposizione per ulteriori informazioni e per discutere insieme di idee e progetti futuri.

Un caro saluto a tutti

Handwritten signature of Nicola Simoni in black ink.